Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-40.
Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-37.
Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002; 99: 3530-9.
Baron F, Turhan AG, Giron-Michel J, et al. Leukemic target susceptibility to natural killer cytotoxicity: Relationship with BCR-ABL expression. Blood 2002; 99: 2107-13.
Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-72.
Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-56.
Issaad C, Ahmed M, Novault S, et al. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia 2000; 14: 662-70.
Druker BJ, Lydon NB. Lessons leamed from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.
Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996; 2: 561-6.
Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-8.
Wolff NC, Ilaria RL, Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 2001; 98: 2808-16.
Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
Druker BJ, Sawyers CL, Kantadian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-52.
Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002; 8: S14-S8.
Appelbaum FR. Perspectives on the future of chronic myeloid leukemia treatment Semin Hematol 2001; 38: 35-42.
McSweeney PA, Niederwieser D, Shizuru J, et al. Hematopeietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-400.
Baron F, Baudoux E, Frère P, et al. Nonmyeloablative stem cell transplantation (NMSCT) with CD8-depleted or CD34-selected PBSC. J Hematother Stem Cell Res 2002; 11: 301-14.
Baron F, Beguin Y. Nonmyeloablative allogeneic hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002; 11: 243-54.
Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-703.
van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001; 358: 1421-3.
